A Decade of Viral Evolution (2015–2025): Emergence, Mutations, and Implications for Global Health

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2025 | Volume : 2 | 02 | Page :
    By

    Satish Kumar Sarankar,

  1. Professor & Principal, Mansarovar Global University, Sehore, M.P., India

Abstract

Over the past decade (2015-2025), viral evolution has profoundly reshaped the global health landscape, challenging healthcare systems, diagnostic tools, therapeutic strategies, and vaccine efficacy. This review comprehensively analyzes the evolutionary trajectories of major human and zoonotic viruses, with a focus on pandemic-prone, drug-resistant, and emerging pathogens. Viral evolution is driven by diverse molecular mechanisms including high mutation rates, recombination, reassortment, host immune pressure, and antiviral interventions, leading to genetic diversification, immune escape, cross-species transmission, and resistance development. SARS-CoV-2 serves as a prime example of real-time viral evolution, with its transition from early variants (Alpha, Beta, Gamma, Delta) to the highly immune-evasive Omicron sublineages (BA.1–BA.5, XBB, JN.1), each shaped by mutations in the spike protein influencing transmissibility and vaccine escape. Influenza A virus continues its seasonal drift and reassortment, notably in H5N1 clade 2.3.4.4b, emphasizing the challenges in surveillance and vaccine matching. Meanwhile, viruses such as Lloviu, Oropouche, and West Nile are expanding their geographic and host range, often unnoticed due to surveillance gaps. Drug-resistant strains of Hepatitis B, HIV-1, and Enterovirus D68 highlight the urgent need for continuous genomic monitoring and therapeutic innovation. Chronic infections foster quasispecies evolution, promoting persistence and treatment failure. Zoonotic spillovers and climate-driven mutations further compound the risks of future outbreaks. This review underscores the necessity of a multidisciplinary “One Health” approach integrating human, animal, and environmental health surveillance. Future directions include leveraging artificial intelligence for predictive viral genomics, developing pan-viral and universal vaccine platforms (e.g., mRNA, nanoparticle-based), and investing in genomic surveillance infrastructure globally. Understanding the decade-long evolution of viruses is critical for preemptive action, vaccine design, public health preparedness, and developing robust antiviral strategies. The insights offered here aim to inform future policies and research directions in an era marked by dynamic viral threats.

Keywords: Virus mutations, Emerging viruses, Global health threats, Zoonotic spillover, SARS-CoV-2 variants, Influenza virus evolution, Impact of virus mutations on vaccines, AI in viral outbreak prediction, Challenges in developing universal vaccines, One Health approach, Vaccine adaptation strategies.

How to cite this article:
Satish Kumar Sarankar. A Decade of Viral Evolution (2015–2025): Emergence, Mutations, and Implications for Global Health. International Journal of Vaccines. 2025; 02(02):-.
How to cite this URL:
Satish Kumar Sarankar. A Decade of Viral Evolution (2015–2025): Emergence, Mutations, and Implications for Global Health. International Journal of Vaccines. 2025; 02(02):-. Available from: https://journals.stmjournals.com/ijv/article=2025/view=234906


References

  1. Mallapaty, S. (2025, January). What will viruses do next? AI is helping scientists predict their evolution. Nature, 637(8046), 527–528.
  2. Zapatero-Belinchón, F. J., Kumar, P., Ott, M., Schwartz, O., & Sigal, A. (2024, September). Understanding emerging and re-emerging viruses to facilitate pandemic preparedness. Nature Microbiology, 9(9), 2208–2211.
  3. Domingo, E. (2020). Molecular basis of genetic variation of viruses: Error-prone replication. In Virus as Populations (pp. 35–71). Elsevier.
  4. Domingo, E., García-Crespo, C., Lobo-Vega, R., & Perales, C. (2021, September 21). Mutation rates, mutation frequencies, and proofreading-repair activities in RNA virus genetics. Viruses, 13(9), 1882.
  5. Shivshankar, P., Karmouty-Quintana, H., Mills, T., Doursout, M. F., Wang, Y., Czopik, A. K., Evans, S. E., Eltzschig, H. K., & Yuan, X. (2022, August). SARS-CoV-2 infection: Host response, immunity, and therapeutic targets. Inflammation, 45(4), 1430–1449.
  6. Lazzarin, A. (2004, April). The role of host immunity in the control of HIV infection: From theory to diagnostic and therapeutic intervention. New Microbiologica, 27(2 Suppl 1), 135–139.
  7. Domingo, E., Martínez-González, B., Somovilla, P., García-Crespo, C., Soria, M. E., de Ávila, A. I., Gadea, I., & Perales, C. (2025, February 19). A general and biomedical perspective of viral quasispecies. RNA, 31(3), 429–443.
  8. Ermonval, M., & Morand, S. (2023, December 20). Viral zoonoses: Interactions and factors driving virus transmission. Viruses, 16(1), 9.
  9. Alizon, S., & Sofonea, M. T. (2025, December). SARS-CoV-2 epidemiology, kinetics, and evolution: A narrative review. Virulence, 16(1), 2480633.
  10. Li, S., et al. (2025). Evolution’s double-edged sword: SARS-CoV-2 adaptation in HIV reveals nature’s safety valve. The Lancet Microbe, 0(0), 101212.
  11. Hart, W. S., Miller, E., Andrews, N. J., Waight, P., Maini, P. K., Funk, S., & Thompson, R. N. (2022, May). Generation time of the alpha and delta SARS-CoV-2 variants: An epidemiological analysis. The Lancet Infectious Diseases, 22(5), 603–610.
  12. Van Nam, L., Dien, T. C., Bang, L. V. N., Thach, P. N., & Van Duyet, L. (2024, March 13). Genetic features of SARS-CoV-2 Alpha, Delta, and Omicron variants and their association with the clinical severity of COVID-19 in Vietnam. IJID Regions, 11, 100348.
  13. Hirotsu, Y., Maejima, M., Shibusawa, M., Natori, Y., Nagakubo, Y., Hosaka, K., Sueki, H., Mochizuki, H., Tsutsui, T., Kakizaki, Y., Miyashita, Y., & Omata, M. (2022, September). Classification of Omicron BA.1, BA.1.1, and BA.2 sublineages by TaqMan assay consistent with whole genome analysis data. International Journal of Infectious Diseases, 122, 486–491.
  14. Rhoden, J., Hoffmann, A. T., Stein, J. F., et al. (2024). Diversity of Omicron sublineages and clinical characteristics in hospitalized patients in the southernmost state of Brazil. BMC Infectious Diseases, 24, 193.
  15. Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., Peacock, S. J., & Robertson, D. L. (2021, July). SARS-CoV-2 variants, spike mutations and immune escape. Nature Reviews Microbiology, 19(7), 409–424.
  16. Wang, S., Hao, Z., Ding, Y., et al. (2025). Characterization of private mutations in the spike protein of SARS-CoV-2 correlates with viral prevalence. BMC Infectious Diseases, 25, 996.
  17. Angius, F., Puxeddu, S., Zaimi, S., Canton, S., Nematollahzadeh, S., Pibiri, A., Delogu, I., Alvisi, G., Moi, M. L., & Manzin, A. (2024, December 28). SARS-CoV-2 evolution: Implications for diagnosis, treatment, vaccine effectiveness and development. Vaccines, 13(1), 17.
  18. Pawar, S. D., Keng, S. S., Tare, D. S., Balakrishnan, A., S., S., Koshy, J., Potdar, V., Vipat, V., Gaikwad, S., Singh, D., Mullick, J., & Kumar, N. (2025, May). Evidence of novel reassortment in clade 2.3.4.4b avian influenza H5N1 viruses, India, 2024. Virology, 606, 110482.
  19. Xie, Z., Yang, J., Jiao, W., Li, X., Iqbal, M., Liao, M., & Dai, M. (2025). Clade 2.3.4.4b highly pathogenic avian influenza H5N1 viruses: Knowns, unknowns, and challenges. Journal of Virology, 99(e00424-25).
  20. Capelastegui, F., & Goldhill, D. H. (2025, June). H5N1 2.3.4.4b: A review of mammalian adaptations and risk of pandemic emergence. Journal of General Virology, 106(6), 002109.
  21. Sooksawasdi Na Ayudhya, S., Leijten, L., Rijnink, W. F., Spronken, M. I., Kuiken, T., Bauer, L., et al. (2025, September). Attachment patterns of avian influenza H5 clade 2.3.4.4b virus in respiratory tracts of marine mammals, North Atlantic Ocean. Emerging Infectious Diseases, 31(9).
  22. Tian, J., Bai, X., Li, M., Zeng, X., Xu, J., Li, P., … Chen, H. (2023). Highly pathogenic avian influenza virus (H5N1) clade 2.3.4.4b introduced by wild birds, China, 2021. Emerging Infectious Diseases, 29(7), 1367–1375.
  23. Zapatero-Belinchón, F. J., Kumar, P., Ott, M., Schwartz, O., & Sigal, A. (2024, September). Understanding emerging and re-emerging viruses to facilitate pandemic preparedness. Nature Microbiology, 9(9), 2208–2211.
  24. Görföl, T., Tóth, G. E., Boldogh, S. A., Jakab, F., & Kemenesi, G. (2022, March). Lloviu virus in Europe is an emerging disease of concern. EcoHealth, 19(1), 5–7.
  25. Desai, A. N., Otter, A., Koopmans, M., Granata, G., Grobusch, M. P., Tunali, V., Astorri, R., Jokelainen, P., Greub, G., Ergönül, Ö., Valdoleiros, S. R., Rovers, C. P., Di Caro, A., Pisapia, R., Fusco, F. M., Pereira do Vale, A., Krogfelt, K. A., Petersen, E., & Atkinson, B. (2024, September 25). Oropouche virus: A re-emerging arbovirus of clinical significance. IJID Regions, 13, 100456.
  26. Kocabiyik, D. Z., Álvarez, L. F., Durigon, E. L., & Wrenger, C. (2025, May 15). West Nile virus – a re-emerging global threat: Recent advances in vaccines and drug discovery. Frontiers in Cellular and Infection Microbiology, 15, 1568031.
  27. Gao, Y. Y., Wang, Q., Liang, X. Y., Zhang, S., Bao, D., Zhao, H., Li, S. B., Wang, K., Hu, G. X., & Gao, F. S. (2023, March). An updated review of feline coronavirus: Mind the two biotypes. Virus Research, 326, 199059.
  28. Liu, J., Xu, L., Ma, X., Bi, Y., & Xin, Y. (2025). Historical and emerging trends in hepatitis B virus integration: A bibliometric visual analysis. Hepatic Medicine, 17, 39–59.
  29. Chemin, I., & Pujol, F. H. (2023, November 27). Updates on hepatitis B virus (HBV) infection 2.0. Microorganisms, 11(12), 2874.
  30. Elrick, M. J., Pekosz, A., & Duggal, P. (2021, January–June). Enterovirus D68 molecular and cellular biology and pathogenesis. Journal of Biological Chemistry, 296, 100317.
  31. Kemp, S. A., Charles, O. J., Derache, A., Smidt, W., Martin, D. P., Iwuji, C., Adamson, J., Govender, K., de Oliveira, T., Dabis, F., Pillay, D., Goldstein, R. A., & Gupta, R. K. (2022). HIV-1 evolutionary dynamics under nonsuppressive antiretroviral therapy. mBio, 13(3), e0026922.
  32. Chakraborty, C., Sharma, A. R., Bhattacharya, M., & Lee, S. S. (2022). A detailed overview of immune escape, antibody escape, partial vaccine escape of SARS-CoV-2 and their emerging variants with escape mutations. Frontiers in Immunology, 13,
  33. Fang, Z., Jiang, W., Liu, P., Xia, N., Li, S., & Gu, Y. (2025). Targeting HIV-1 immune escape mechanisms: Key advances and challenges in HIV-1 vaccine design. Microbiological Research, 299,
  34. Russell, C. A., Fouchier, R. A. M., Ghaswalla, P., Park, Y., Vicic, N., Ananworanich, J., Nachbagauer, R., & Rudin, D. (2024). Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines. Human Vaccines & Immunotherapeutics, 20(1), 2336357.
  35. Clemens, S. A. C., & Clemens, R. (2023). The need and challenges for development of vaccines against emerging infectious diseases. Journal of Pediatrics (Rio de Janeiro), 99(Suppl 1), S37–S45.
  36. Miller, I. F., & Metcalf, C. J. (2019). Vaccine-driven virulence evolution: Consequences of unbalanced reductions in mortality and transmission and implications for pertussis vaccines. Journal of the Royal Society Interface, 16(161), 20190642.
  37. Bull, J. J., & Antia, R. (2022). Which “imperfect vaccines” encourage the evolution of higher virulence? Evolution, Medicine, and Public Health, 10(1), 202–213.
  38. Gebre, M. S., Brito, L. A., Tostanoski, L. H., Edwards, D. K., Carfi, A., & Barouch, D. H. (2021). Novel approaches for vaccine development. Cell, 184(6), 1589–1603.
  39. Edelstein, M., Lee, L. M., Herten-Crabb, A., Heymann, D. L., & Harper, D. R. (2018). Strengthening global public health surveillance through data and benefit sharing. Emerging Infectious Diseases, 24(7), 1324–1330.
  40. Athanasopoulou, K., Michalopoulou, V. I., Scorilas, A., & Adamopoulos, P. G. (2025). Integrating artificial intelligence in next-generation sequencing: Advances, challenges, and future directions. Current Issues in Molecular Biology, 47(6), 470.
  41. Tan, C. W., Valkenburg, S. A., Poon, L. L. M., & Wang, L. F. (2023). Broad-spectrum pan-genus and pan-family virus vaccines. Cell Host & Microbe, 31(6), 902–916.
  42. Kelly, T. R., Machalaba, C., Karesh, W. B., Crook, P. Z., Gilardi, K., Nziza, J., Uhart, M. M., Robles, E. A., Saylors, K., Joly, D. O., Monagin, C., Mangombo, P. M., Kingebeni, P. M., Kazwala, R., Wolking, D., Smith, W., & Mazet, J. A. K. (2020). Implementing One Health approaches to confront emerging and re-emerging zoonotic disease threats: Lessons from PREDICT. One Health Outlook, 2,
  43. Lal, A., Abdalla, S. M., Chattu, V. K., Erondu, N. A., Lee, T. L., Singh, S., Abou-Taleb, H., Vega Morales, J., & Phelan, A. (2022). Pandemic preparedness and response: Exploring the role of universal health coverage within the global health security architecture. The Lancet Global Health, 10(11), e1675–e1683.
  44. Frazer, I. H. (2020). Collaboration in the war against viruses: A multidisciplinary international effort. Innovation, 1(1), 100011.
  45. Yu, X., He, Q., & Kong, Q. (2024). Multidisciplinary approaches to combat emerging viruses: Diagnostics, therapeutic gene and vaccine delivery, and nanotherapeutics. Frontiers in Microbiology, 15,
Ahead of Print Subscription Review Article
Volume 02
02
Received 12/08/2025
Accepted 03/09/2025
Published 27/12/2025
Publication Time 137 Days
182

Login


My IP

PlumX Metrics